Clinical case of acute lymphoblastic leukemia under the mask of mononucleosis
PRACTICAL NOTES
Abstract
Acute lymphoblastic leukemia is the most common oncopathology among children and adolescents, most often occurring before the age of 18. The peak incidence occurs in preschool age from 2 to 5 years, according to statistics, it is more common in boys. On its share accounts for 75–80% of all tumor processes of the hematopoietic system in children (3–4 cases per 100 thousand children). The causes of the development of malignant disease are still not fully known, in the absence of timely diagnosis and therapy, it inevitably leads to an unfavorable outcome. Clinical the picture is nonspecific and is determined by the degree of dysfunction of the bone marrow (anemia, hemorrhagic syndrome, lymphadenopathy, damage to the liver, spleen, mediastinum, central nervous system, skin, testicles, etc.). In the organs of hematopoiesis, the process of maturation of lymphocytes that protect the body from infectious agents is disrupted, the number of immature white blood cells (blasts) sharply increases, which replace normal blood cells and cause the development of acute lymphoblastic leukemia symptoms. The deficiency of full-fledged leukocytes leads to a decrease in immunity and the development of foci of infection. Patients can complain of weakness, pallor, fever, malaise, sore throat, pain in the bones and/or joints, bleeding of the mucous membranes, enlarged lymph nodes, etc. All the observed symptoms are not specific to acute lymphoblastic leukemia and can be associated with other diseases, which often complicates the correct and timely diagnosis. We present a case of acute lymphoblastic leukemia in a patient aged 8 years and 5 months, hospitalized with a diagnosis of “Infectious mononucleosis”. A special feature of this case was the atypical debut of acute lymphoblastic leukemia in a child.
References
1. Brown P., Inaba H., Annesley C., Beck J., Colace S., Dallas M. et al. Pediatric Acute Lymphoblasric Leukemia, Version 2.2020. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(1):81–112. https://doi.org/10.6004/jnccn.2020.0001.
2. Siegel D.A., Henley S.J., Li J., Pollack L.A., Van Dyne E.A., White A. Rates and Trends of Pediatric Acute Lymphoblastic Leukemia — United States, 2001–2014. MMWR Morb Mortal Wkly Rep. 2017;66(36):950–954. https://doi.org/10.15585/mmwr.mm6636a3.
3. Чернова Т.М., Яковлева Т.В. Трудности диагностики лимфомы Ходжкина, ассоциированной с вирусом Эпштейна–Барр. Медицинский совет. 2017;(9):144–147. https://doi.org/10.21518/2079-701X-2017-9-144-147.
4. Тимченко В.Н., Хмилевская С.А. Болезни цивилизации (корь, ВЭБ-мононуклеоз) в практике педиатра. СПб.: Спец Лит; 2017. 527 с.
5. Сергиенко Е.Н., Романова О.Н., Артемчик Т.А., Сергей Ж.С., Кашкан А.М., Карась О.В. Лейкоз у ребенка под маской мононуклеозоподобного синдрома. Медицинский журнал. 2028;(2):149–152. EDN: XQYJET.
6. Литвинов Д.В., Карелин А.Ф., Романова К.И., Румянцева Ю.В., Карачунский А.И. Лечение острого лимфобластного лейкоза у детей: современные возможности и нерешенные проблемы. Доктор.Ру. 2015;(10):30–37. EDN: UCDIWT.
7. Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®) — Health Professional Version. 2024. National Cancer Institute. URL: https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq (дата обращения: 03.04.2026).
8. Swerdlow S.H., Campo E., Harris N.L. et al. С lassification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC); 2017. 585 p.
9. Bene M.C., Castoldi G., Knapp W., Ludwig W.D., Matutes E., Orfao A., van’t Veer M.B. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9(10):1783–1786.
10. Литвинов Д.В., Тесаков И.П., Шелихова Л.Н., Хачатрян Л.А., Зеркаленкова Е.А., Ольшанская Ю.В. и др. Острый лимфобластный лейкоз с транслокацией t (17;19): надежда появилась! Описание случая мультимодальной иммунотерапии у ребенка 3 лет с рефрактерным течением заболевания. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2022;21(3):100–114. https://doi.org/10.24287/1726-1708-2022-21-3-100-114.
11. Острый лимфобластный лейкоз у детей. Клинические рекомендации РФ (2024). Российское общество детских онкологов и гематологов. URL: https://diseases.medelement.com/disease/острый-лимфобластный-лейкоз-у-детей-кр-рф-2024/18554 (дата обращения: 03.04.2026).
12. Bhojwani D., Yang J.J, Pui C.-H. Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62(1): 47–60. https://doi.org/10.1016/j.pcl.2014.09.004.
13. Ahmad I., Ghafoor T., Ullah A., Naz S., Tahir M. et al. Pediatric acute lymphoblastic leukemia: clinical characteristics, treatment outcomes, and prognostic factors: 10 years’ experience from a low- and middle-income country. JCO Glob Oncol. 2023:9:e2200288. https://doi.org/10.1200/GO.22.00288.
14. Федорова А.В., Тимченко В.Н., Баннова С.Л. др. Аутоиммунные и лимфопролиферативные злокачественные заболевания, ассоциированные с Эпштейна–Барр вирусной инфекцией. Педиатр. 2019;10(4):89–96. https://doi.org/10.17816/ped10489-96.
15. Inaba H., Pui C.-H. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J Clin Med. 2021;10(9):1926. https://doi.org/10.3390/jcm10091926.
16. Lv M., Liu Y., Liu W., Xing Y., Zhang S. Immunotherapy for pediatric acute lymphoblastic leukemia: recent advances and future perspectives. Front Immunol. 2022:13:921894. https://doi.org/10.3389/fimmu.2022.921894.



